Current Research
The types of research currently undertaken at the Trust are varied, from complex clinical trials, qualitative health service research, registries, post-marketing surveillance to trainee doctors and students doing low risk, own account studies. Much of this research has been adopted by the National Institute of Health Research, with a small number of commercial/pharmaceutical research making up the rest.
Cancer Research
Breast
ATNEC: A randomised trial investigating the requirement for axillary treatment, after chemotherapy, for patients with early stage breast cancer.
Principal Investigator (PI): Ms Werbena Hamilton-Burke
Colorectal
Yorkshire Cancer Research Bowel Cancer Improvement Program: Does intensive multidisciplinary team intervention improve bowel cancer outcomes in Yorkshire.
Principal Investigator (PI): Ms Paula Pickersgill
OnCoRe: Oncological Outcomes after Clinical Complete Response (cCR) in patients with rectal cancer.
Principal Investigator (PI): Miss Tamsyn Grey
FOxTROT2: Personalising neo-adjuvant Chemotherapy in Locally advanced but operable colon cancer. A randomised trial programme.
Principal Investigator (PI): Dr Sam Turnbull
FOxTROT3: A phase III randomized trial evaluating neoadjuvant chemotherapy with mFOLFOXIRI compared with neoadjuvant OxFp in patients with locally advanced but operable colon cancer
Principal Investigator (PI): Dr Sam Turnbull
ARIEL: A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL).
Principal Investigator (PI): Dr Sam Turnbull
TRACC-C: Tracking mutations in cell free tumour DNA to predict relapse in early colorectal cancer.
Principal Investigator (PI): Dr Sam Turnbull
Haematology
CML Registry: The study programme to investigate modern trends in Chronic Myeloid Leukemia (CML).
Principal Investigator (PI): Dr Kate Rothwell
EUMDS: A prospective, multicentre European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes
Principal Investigator (PI): Dr Kate Rothwell
RADAR (UK-MRA Myeloma XV): Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE).
Principal Investigator (PI): Dr Sylvia Feyler
BGB-3111-308: A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma.
Prinicipal Investigator (PI): Dr Sylvia Feyler
COSMOS: Characterising risk and biology Of Smouldering Myeloma for early detection Of Symptomatic myeloma.
Prinicipal Investigator (PI): Dr Sylvia Feyler
ProMMise-D: Belamaf + Bortezomib + Dexamethasone Triplet: Ocular Study.
Prinicipal Investigator (PI): Dr Sylvia Feyler
Lung
REFINE-LUNG: A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design.
Principal Investigator (PI): Dr Emma Rathbone
SUNRAY-01: A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing FirstLine Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression.
Principal Investigator (PI): Dr Emma Rathbone
SUNRAY-02: A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer.
Principal Investigator (PI): Dr Emma Rathbone
BNT327-03: A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer.
Principal Investigator (PI): Dr Emma Rathbone
Pancreatic
UK-EDI: UK Early Detection Initiative for Pancreatic Cancer.
Principal Investigator (PI): Dr Sabari Haridass
Urology
BC-RECON: Diagnosing Bladder Cancer- evaluating the role of a urinary biomarker test in the Reconfiguration of the haematuria clinic investigations.
Principal Investigator (PI): Mr Tahir Qayyum
ORION-BC: A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCGunresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease.
Principal Investigator (PI): Mr Tahir Qayyum
Other
ICI Genetics: Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity. Participants recruited from all forms of cancer.
Principal Investigator (PI): Dr Emma Rathbone
APPROACH: An app for health & wellbeing after cancer – a randomised controlled trial.
Prinicipal Investigator (PI): Zuleikha Mulla
Other Specialty Research
Cardiovasular
EASY-AS: A Randomised Controlled Trial of Early valve replacement in severe ASYmptomatic Aortic Stenosis.
Principal Investigator (PI): Dr Hossam Elmahy
AMEND-CRT: Assessment of Mechanical Dyssynchrony as Selection Criterion for Cardiac Resynchronisation Therapy.
Principal Investigator (PI): Dr Hossam Elmahy
EASi-HF: A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) ≥40%.
Principal Investigator (PI): Dr Azeem Sheikh
CHART: Comprehensive geriatric assessment (CGA) to sustain independence for older people living with heart failure with preserved ejection fraction (HFpEF) and frailty.
Principal Investigator (PI): Dr Hossam Elmahy
EASI-HF Reduced: A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%.
Principal Investigator (PI): Dr Azeem Sheikh
PROFID EHRA: PRevention Of sudden cardiac death aFter myocardial Infarction by Defibrillator implantation.
Principal Investigator (PI): Dr Hossam Elmahy
Critical Care
SIGNET: Statins for Improving Organ Outcome in Transplantation.
Principal Investigator (PI): Dr Paul Knight
MOSAICC: Evaluating the clinical and cost-effectiveness of Sodium Bicarbonate administration for critically ill patients with Acute Kidney Injury and metabolic acidosis.
Principal Investigator (PI): Dr Aaron Corp
SepTIC: Sepsis Trials in Critical Care.
Principal Investigator (PI): Dr Aaron Corp
Dermatology
BADBIR: British Association of Dermatologists Biologics and Immunomodulators Register
Principal Investigator (PI): Tracy Tatchell-Adams
Diabetes & Endocrinology
PROTECT: PRegnancy Outcomes using continuous glucose monitoring TEChnology in pregnant women with early-onset Type 2 diabetes.
Principal Investigator (PI): Dr Julie Kway-Tun
Frequency of Ketosis in People Living with Diabetes or Other Medical Conditions
Principal Investigator (PI): Dr Rob Moisey
IMVT-1402-2502: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease.
Principal Investigator (PI): Dr Rob Moisey
Emergency Care
CRASH-4: Intramuscular tranexamic acid for the treatment of symptomatic mild traumatic brain injury in older adults: a randomised, double-blind, placebo-controlled trial.
Principal Investigator (PI): Dr Huw Masson
ENT
STARFISH: A randomised controlled trial of STeroid Administration Routes For Idiopathic Sudden sensorineural Hearing loss.
Principal Investigator (PI): Dr George Elmaraghi
Gastroenterology
IBD BioResource: The UK Inflammatory Bowel Disease Bioresource: Progressing from Genetics to Function and Clinical Translation in Crohn's Disease & Ulcerative Colitis.
Principal Investigator (PI): Dr Sunil Sonwalker
GONDOMAR: Goals, Needs and outcome Determinants Of Multimodal therapy in Perianal Crohn's fistula.
Principal Investigator (PI): Dr Mohammed Allah-Ditta
ABX464-105: A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis.
Principal Investigator (PI): Dr Mohamed Yousif
MK7240-001: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis.
Principal Investigator (PI): Dr Mohamed Yousif
MK7240-008: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to
Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely
Active Crohn’s Disease.
Principal Investigator (PI): Dr Mohamed Yousif
Haematology
MDS Registry for newly diagnosed patients: A prospective, multicentre European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes
Principal Investigator (PI): Dr Kate Rothwell
Hepatology
PBC Genetics Study: Investigation of the Genetic and Molecular Pathogenesis of Primary Biliary Cirrhosis.
rincipal Investigator (PI): Dr Susan Jones
Infection
DURATION-UTI: Impact of duration of antibiotic treatment on symptoms, recovery and antibiotic resistance in adult women with urinary tract infections (UTIs): a randomised controlled trial.
Principal Investigator (PI): Dr Rangaprasad Karadi
TILIA: A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen.
Principal Investigator (PI): Dr Yaqoob Ghumro
Musculoskeletal
BSRBR: Toxicity from biologic therapy
Principal Investigator (PI): Dr Omer Sharif
Obstetric & Gynaecology
TTTS Registry: A physician-run Multiple Pregnancy Registry in collaboration with the Twin & Multiple Births Association (TAMBA), designed to serve the interests of patients while overcoming challenges of sharing data over great distances while protecting patient privacy.
Principal Investigator (PI): Dr Fifydani Shamsudin
CAPE: Calcium Supplementation for Prevention of Pre-eclampsia in High Risk Women.
Principal Investigator (PI): Dr Fifydani Shamsudin
MINESS 20-28: Mothers Working to Prevent Early Stillbirth Study 20-28.
Principal Investigator (PI): Rebecca Leon
OBS UK: Clinical and cost-effectiveness of a maternity quality improvement programme to reduce excess bleeding and need for transfusion after childbirth.
Principal Investigator (PI): Mohamed Wahby
FEEL-GOOD: Female Empowerment through Enhanced Living: a comparison of vaGinal continence devices and pelvic flOOr muscle training (PFMT) versus PFMT only for female stress urinary incontinence: a feasibility and pilot StuDy. Stage 2
Principal Investigator (PI): Miss Yi Ling Chan
GILD: The clinical and cost effectiveness of tight versus more relaxed glucose control around the time of birth in pregnancies complicated by gestational diabetes.
Prinicipal Investigator (PI): Dr Julie Goddard
Ophthalmology
UK MPTLT Study: MP Transscleral Laser Therapy: A Prospective Interventional Post-Market Clinical Device Study UK Study.
Principal Investigator (PI): Mr Francesco Pillitteri
Paediatric
Cleft Collective: Cohort Studies - a large DNA backed prospective resource for the study of the genetic and environmental determinants of cleft lip and/or palate and the long term outcomes in children with cleft lip and/or palate.
Principal Investigator (PI): Rebecca Leon
FEED1 - Fluids Exclusively Enteral from Day 1: A randomised controlled trial of full milk feeds versus intravenous fluids with gradual feeding for preterm infants (30-33 weeks gestational age).
Principal Investigator (PI): Dr Abdul Mattara
WHEAT: WithHolding Enteral Feeds Around Blood Transfusion – the WHEAT International Trial.
Principal Investigator (PI): Dr James Houston
MAPS: Mental Health Admissions to Paediatric Wards Study - WP2 & WP3.
Principal Investigator (PI): Angie Salmons
SPIROMAC: SPIROmetry to Manage Asthma in Children.
Principal Investigator (PI): Dr James Houston
NeoGASTRIC: Avoiding routine gastric residual volume measurement in neonatal critical care: a multi-centre randomised controlled trial.
Principal Investigator (PI): Dr Karin Schwarz
Physiotherapy
RaCeR 2: Clinical and cost-effectiveness of individualised (early) patient-directed rehabilitation versus standard rehabilitation after surgical repair of the rotator cuff of the shoulder: a multi-centre, randomised controlled trial with integrated Quintet Recruitment Intervention.
Principal Investigator (PI): Tash Maher
Renal & Urogenital
RADAR: National Studies of Rare Kidney Diseases
Principal Investigator (PI): Dr Rahul Vundru
Respiratory
ASPECT: Aspirin after hospitalisation with pneumonia to prevent cardiovascular events randomised controlled trial.
Principal Investigator (PI): Dr Purav Desai
SENSOR: Physiological and environmental data in a remote setting to predict exacerbation events in patients with chronic obstructive pulmonary disease: an observational study
Principal Investigator (PI): Dr Andrew Hardy
EMBARK: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease.
Principal Investigator (PI): Dr Andrew Hardy
Stroke
MAPS-2: Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial.
Principal Investigator (PI): Dr Syed Ahmad
LIBREXIA STROKE: A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack.
Principal Investigator (PI): Dr Tariq Salman
Surgical
MEErKAT: Mesenteric Excision and Kono-S Anastomosis Trial
Principal Investigator (PI): Mr Simon Gonsalves
E-BRIC: Early bowel resection for terminal ileal Crohn’s disease: exploring patients’ and clinicians’ perspectives and barriers to implementation.
Principal Investigator (PI): Miss Tamsyn Grey
RESPOND study (Rescue for Emergency Surgery Patients Observed to uNdergo acute Deterioration) Work Package 4: A cluster-randomised stepped-wedge Trial of a complex Human Factors intervention.
Principal Investigator (PI): Mr Arin Saha
OCEAN: Optimisation before Crohn’s surgery using Exclusive Enteral Nutrition.
Principal Investigator (PI): Mr Muneer Junejo
Trauma & Orthopaedics
DIDACT: Surgery compared with sling immobilisation in the management of adults with a
displaced fracture of the distal clavicle: a multi-centre, pragmatic, parallel group,
non-inferiority, randomised controlled trial.
Principal Investigator (PI): Mr Neil Pennington
REPPORT: REcurrent Patellar dislocation: Personalised therapy or OpeRative Treatment?
Principal Investigator (PI): Mr Osman Riaz
Studies In Follow-Up
Accident & Emergency
HUSH:The Humeral Shaft Fracture Trial: A multi-centre Prospective Randomised Superiority Trial of Surgical Versus Non-Surgical Interventions for Humeral Shaft Fractures in Patients Aged 18 Years or Older.
Principal Investigator (PI):Mr Simon Fogerty
Cancer
Add-Aspirin: A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Principal Investigator (PI): Dr Jo Dent
FAST-Forward: To Identify A 5-Fraction Schedule Of Curative Radiotherapy Delivered In 1 Week That Is At Least As Effective And Safe As The Current UK Standard 15-Fraction Regimen Delivered Over 3 Weeks Following Primary Surgery For Early Breast Cancer.
Principal Investigator (PI): Mr Neil Roberts
FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab, A phase III, multicentre, randomised, controlled, open, parallel group trial in patients with previously untreated CLL.
Principal Investigator (PI): Dr Kate Rothwell
Genetics of Endometrial Cancer: A population based study of genetic predisposition and gene-environment interactions in endometrial cancer.
Principal Investigator (PI): Dr Uschi Hofmann
SKYSCRAPER: A Phase III, Open-label, Randomised Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer Who have not progressed After Concurrent Platinum-based Chemo Radiation.
Principal Investigator (PI): Dr Emma Rathbone
HORIZONS:Understanding the impact of cancer diagnosis and treatment.
Principal Investigator (PI): Mrs Georgina Turner
IRAMP: A Study Exploring Research Access for People with Mesothelioma via Interviews with Patients, Carers and Health Care Professionals Who Have Experience of the Condition.
Principle Investigator (PI): Mr Simon Bolton
IMreal: A Non-Interventional, Multicenter, Multiple Cohort Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions In Patients Treated in Routine Clincial Practice.
Principal Investigator (PI):Dr Nick Brown
LI-1: Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial.
Principal Investigator (PI): Dr Kate Rothwell
MaPLe:Molecular profiling for lymphoma.
Principle Investigator (PI): Dr Kate Rothwell
Myeloma XII (ACCoRd trial): A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT Consolidation and maintenance strategy in patients with Relapsed multiple myeloma.
Principal Investigator (PI): Dr Sylvia Feyler
Myeloma XIV (FiTNEss): Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).
Principal Investigator (PI): Dr Sylvia Feyler
NIMBLE: Nodule Immunophenotyping biomarker for lung cancer early diagnosis study.
Principal Investigator (PI): Dr Steven Thomas
PATCH: Prostate Adenocarcinoma: TransCutaneous Hormones: A Randomised Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer.
Principal Investigator (PI): Dr Uschi Hofmann
POETIC: Trial of Perioperative Endocrine Therapy - Individualising Care.
Principal Investigator (PI): Dr Werbena Hamilton-Burke
PrecisionPanc: Advancing personalised medicine treatment strategies for pancreatic cancer.
Principal Investigator (PI): Dr Emma Rathbone
PRIMETIME: Post-operative avoidance of radiotherapy: biomarker selection of women categorised to be in a very low risk group by IHC4+C.
Principal Investigator (PI): Mr Neil Roberts
PRIMUS 001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation.
Principal Investigator (PI): Dr Emma Rathbone
RaNGO: Rare Neoplasms of Gynaecological Origin.
Principal Investigator (PI): Dr Deivasikamani Ramanujam
ROSCO: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy.
Principal Investigator (PI): Dr Deivasikamani Ramanujam
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy.
Principal Investigator (PI): Dr Uschi Hofmann
MARECA: National study of management of breast cancer locoregional recurrence and oncological outcome.
Principal Investigator (PI): Dr Richard Frame
UKALL 2011: United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011.
Principal Investigator (PI): Dr Gill Sharpe
UNIRAD: Randomized, Double-Blind, Multicentre Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women with Poor Prognosis, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease.
Principal Investigator (PI): Dr Jo Dent
Cardiovascular
EVAREST:The Use of Blood Biomarkers, Including Extracellular Vesicles, to Improve the Diagnostic Accuracy of Cardiac Assessment by Stress Echocardiogram.
Principal Investigator (PI): Dr Azeem Sheikh
ZODIAC: OptimiZation of Lipid Lowering Therapies Using a DSS in ACS: Implementation of a Decision Support System and its Effect On Early Optimisation of Lipid-Lowering Therapies in Patients with Acute Coronary Syndrome: A Cluster Randomised Controlled Trial.
Principal Investigator (PI): Dr Azeem Sheikh
ORION-4:A Double-Blind Randomised Placebo-Controlled Trial Assessing the Effects of Inclisiran On Clinical Outcomes Among People with Atherosclerotic Cardiovascular Disease.
Principal Investigator (PI): Dr Sabari Haridass
Gastroenterology
CLARITY IBD: Impact of Biologic Therapy on SaRs-Cov-2 Infection and Immunity.
Principal Investigator (PI): Dr Sunil Sonwalkar
M14-533: A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis.
Principal Investigator (PI): Dr Sunil Sonwalkar
Endocrinology
IS354CS5: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.
Principal Investigator (PI):Dr Sabari Haridass
Maternity
CHAPTER: Childbirth Acquired Perinatal Trauma Study; a Cohort Study.
Principal Investigator (PI): Dr Tina Verghese
GBS3: The Clinical and Cost-Effectiveness of Testing for Group B Streptococcus: A Cluster Randomised Trial with Economic and Acceptability Evaluations.
Principal Investigator (PI): Dr Julie Goddard
SUNNY:A Randomised Controlled Trial to Investigate the Feasibility and Acceptability of Snacktivity™ in Pregnant Women.
Principal Investigator (PI): Ms Melanie Struthers
Paediatrics
AZTEC2: Long Term Follow-Up of Azithromycin Therapy for Chronic Lung Disease of Prematurity The AZTEC 2 (Azithromycin Therapy for Chronic Lung Disease 2)
Principal Investigator (PI): Dr James Houston
Azithromycin Therapy for Chronic Lung Disease of Prematurity: A Randomised, Placebo Controlled Trial of Azithromycin for the Prevention of Chronic Lung Disease of Prematurity in Pre-Term Infants.
Principal Investigator (PI):Dr James Houston
Genetic Determinants of Kawasaki Disease: Genetic Determinants of Kawasaki Disease for Susceptibility and Outcome.
Principal Investigator (PI): Dr Khaleel-Ur Rahman
SINEPOST:SARS-CoV-2 Infection in Neonates or in Pregnancy: Outcomes at Eighteen months.
Principal Investigator (PI):Mrs Georgina Turner
CF START: The Cystic Fibrosis (CF) Anti-Staphylococcal Antibiotic Prophylaxis Trial (CF START), A Randomised Registry Trial to Assess the Safety and Efficacy of Flucloxacillin as a Long-Term Prophylaxis Agent for Infants with CF.
Principal Investigator (PI): Dr James Houston
Physiotherapy
WISE: Wrist Injury Strengthening Exercise: Progressive Resistance and Flexibility Exercises Versus Usual Care Advice for Improving Pain and Function After Distal Radius Fracture in Adults Aged 50 Years or Over: the WISE Randomised Superiority Trial.
Principal Investigator (PI): Ms Claire Paxman
Radiology
MIDI: Deep Learning for Identification of Abnormalities on Head MRI.
Principal Investigator (PI):Mrs Georgina Turner
Sexual Health
C2C: COMBINE-2 for Cabotegravir+Rilpivirine LA Regimen.
Principal Investigator (PI): Dr Emma Street
Stroke
ENRICH-AF: Edoxaban for IntraCranial Haemorrhage Survivors with AF.
Principal Investigator (PI):Dr Syed Ahmad
OPTIMAS: Optimal Timing of Anticoagulation After Acute Ischaemic Stroke: A Randomised Controlled Trial.
Principal Investigator (PI): Dr Manohar Kini
Surgical
RECOVER TOGETHER: Improving Recovery After Bowel Cancer Surgery: Mixed-Method Feasibility Study of a Co-Produced Information Intervention.
Principal Investigator (PI): Ms Claire MacDonald
Trauma & Orthopaedics
PROFHER2: A Three-Arm Randomised Controlled Trial to Assess the Effectiveness and Cost-Effectiveness of Reverse Shoulder Arthroplasty Versus Hemiarthroplasty Versus Non-Surgical Care for Acute Three and Four-Part Fractures of the Proximal Humerus in Patients Over 65 Years of Age – Proximal Fracture of the Humerus: Evaluation by Randomisation Trial No.2.
Principal Investigator (PI):Mr Neil Pennington
SYNC01: Development of a new Patient Reported Outcome Measure (PROM) to assess patient’s emotional wellbeing and perceptions of Total Knee Replacement surgery for the treatment of knee arthritis.
Principal Investigator (PI): Dr Andreea Jimenez
